TITLE

Availability of Cefixime 400 mg Tablets -- United States, April 2008

PUB. DATE
April 2008
SOURCE
MMWR: Morbidity & Mortality Weekly Report;4/25/2008, Vol. 57 Issue 16, p435
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This article reports on the availability of cefixime 400 milligram tablets in the U.S. starting April 2008. Lupin Pharmaceuticals Inc. will be providing the drug. The firm received Food and Drug Administration approval in February 2004 to manufacture and market cefixime. Its availability had been limited since July 2002, when Wyeth Pharmaceuticals discontinued manufacturing cefixime tablets.
ACCESSION #
31889108

 

Related Articles

  • Suprax 400mg Capsules.  // Monthly Prescribing Reference;Jul2012, Vol. 28 Issue 7, pA7 

    The article informs about the approval of Lupin Pharmaceuticals Inc.'s Suprax drug by the U.S. Food and Drug Administration.

  • FDA nod to generic Cymbalta capsules.  // BioSpectrum;Jan2012, Vol. 10 Issue 1, p78 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) for the Duloxetine Hydrochloride Delayed-release (HCl DR) capsules from Lupin Pharmaceuticals Inc.

  • Lupin wins FDA tentative approval for insomnia drug.  // PharmaWatch: CNS;May2010, Vol. 9 Issue 5, p9 

    The article discusses the tentative approval that the Food & Drug Administration (FDA) has granted to Lupin Pharmaceuticals Inc. for its new drug application for eszopiclone tablets.

  • Wyeth Pharmaceuticals, Inc.; Withdrawal of Approval of a New Drug Application for DURACT Capsules. Woodcock, Janet // Federal Register (National Archives & Records Service, Office of;7/9/2012, Vol. 77 Issue 131, p40367 

    The article presents a notice from the U.S. Food and Drug Administration (FDA) on its withdrawal of the approval of a drug application of Wyeth Pharmaceuticals Inc. for DURACT Capsules as requested by Wyeth.

  • Lupin Receives Tentative FDA Approvals for Generic Nuvigil® Tablets and Generic Oracea® Capsules.  // World Energy News;7/31/2013, p13 

    The article reports on the U.S. Food and Drug Administration's (FDA) approval of Lupin Pharmaceuticals Inc.'s armodafinil tablets and doxycycline capsules. Lupin's armodafinil is the AB-rated generic equivalent of Cephalon's stimulant-like drug Nuvigil. Lupin's doxycycline is an AB-rated generic...

  • Lupin recalls two lots of antibiotic drug in US market.  // FRPT- Chemical Snapshot;4/27/2014, p19 

    The article discusses a report from the U.S. Food and Drug Administration that pharmaceutical company Lupin Pharmaceuticals Inc. based in Mumbai, India is voluntarily recalling more than 9,000 bottles of Suprax, an antibiotic drug for the treatment of bacterial infections, in the U.S. market. It...

  • New drugs.  // Drug Topics;Aug2012, Vol. 156 Issue 8, p43 

    The article reports on the newly approved drugs by the U.S. Food and Drug Administration in 2012. These include Belviq from Eisai and Arena Pharmaceuticals, Suprax 400 milligram capsules from Lupin Pharmaceuticals Inc., and Gammagard Liquid 10% from Baxter. Information about the use of these...

  • Effexor ad cited by FDA as misleading. J. G. D. // Medical Marketing & Media;Feb2008, Vol. 43 Issue 2, p17 

    The article reports on the comment made by the U.S. Food and Drug Administration's (FDA) Division of Drug Marketing, Advertising and Communications regarding Wyeth Pharmaceuticals' professional journal advertisement for Effexor XR or venlaxine hydrochloride (HCl). According to the FDA, the...

  • Torisel approved for advanced kidney cancer. Traynor, Kate // American Journal of Health-System Pharmacy;7/15/2007, Vol. 64 Issue 14, p1460 

    The article reports that the U.S. Food and Drug Administration has approved the marketing of temsirolimus injection, or Torisel, for the treatment of patients with advanced renal cell carcinoma. Temsirolimus, from Wyeth Pharmaceuticals, inhibits the mammalian target of rapamycin kinase, which is...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics